胃癌、食管癌中NY-ESO-1抗原特异性免疫应答与生存率的关系研究

Antigen expression and cellular immunogenicity of NY-ESO-1 in gastric and esophageal cancer

目的分析胃癌、食管癌中NY-ESO-1抗原基因的表达分布、NY-ESO-1157-165表位引发的特异性细胞免疫应答的状态与生存率的关系。方法利用RT-PCR方法检测112例胃癌和76例食管癌患者肿瘤标本和正常胃黏膜中NY-ESO-1抗原基因的表达,应用多色流式分析结合HLA-A2限制性表位肽/五聚体复合物技术对胃癌、食管癌患者外周血NY-ESO-1157-165表位特异性CTL进行精确定量。回顾分析20例NY-ESO-1+/HLA-A2+患者,随访3年,比较不同免疫应答状态对生存率的影响。结果食管癌患者中NY-ESO-1mRNA表达频率(36.8%)明显高于胃癌(13.4%)。在20例检测到的NY-ESO-1+HLA-A2+患者中,强反应者(CD8+pentamer+cells≥0.5%)生存率明显高于弱反应者(CD8+pentamer+cells<0.5%)(P<0.01)。结论胃癌、食管癌患者均有不同程度表达NY-ESO-1,其特异性免疫应答被检测到,并与生存率有关。

Objective To analyze the relationship between the CTL response of NY-ESO-1 in gastric and esophageal cancer and survival rate in Chinese in order to provide data to develop a vaccine against the NY- ESO-1 positive cancer. Methods One hundred and twelve gastric cancer specimens and seventy-six esophageal cancer specimens were analyzed for the expression of NY-ESO-1 mRNA by RT-PCR. Pentamer staining were performed to analyze the frequency of NY-ESO-1157-165 specific CTL in NY-ESO-1/HLA-A2 positive patients. The correlation of CTL response and survival rate were analyzed. Results About 13.4% of the gastric cancer and 36.8% of the esophageal cancer were NY-ESO-1 positive. There were 23 patients with NY-ESO-1/HLA- A2 double positive. Frequency of Pentamer staining analysis and survival rate of these NY-ESO-1/HLA-A2 double positive patients indicated that high survival rate correlate with strong cellular immune response. Conclusion NY-ESO-1 expression is found in some of gastric and esophageal cancer, and NY-ESO-1157-165 peptide can be regarded as a candidate for vaccination due to their expression and CTL response.